---
title: "Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A,… — 瑞銀 — DecisionGateway"
description: "statement by 瑞銀, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b"
meta:
  "og:description": "statement by 瑞銀, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A,… — 瑞銀 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

statement

# **Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.**

A statement by [**瑞銀**](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *泰格醫藥還計劃將約60%的淨現金收益用於海外臨床CRO擴張和併購，20%用於日常運營，剩餘的約20%可能用於分紅或股票回購。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715728)

[**瑞銀 dossier **](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54)

## **Discussion**

## **Related claims**

[**Tigermed also plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% may be used for dividends or share buybacks.**瑞銀 · commitment](https://dgw.tmarket.io/claims/01a1e74c-c2dd-7554-8065-e559c4723dac) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**If the transaction is completed, Tigermed can also divest non-core businesses, including overseas laboratories, CMC and genomics, to focus more on clinical CRO services.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e74c-c2d0-77b8-a467-e3dc1b82410e) [**After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df) [**Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D competitiveness.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d) [**Tigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3011-7670-a475-41411a6a82cf)

## **More claims by 瑞銀**

[**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**Frontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.**statement](https://dgw.tmarket.io/claims/01a1e751-3054-7ca0-a7ed-2ee97b0ffbc4) [**After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**statement](https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df) [**The cancellation price per Frontage Holdings share is HK$2.37, a 107.2% premium to the 360-day average share price, equivalent to about 91.6 times Frontage's 2025 price-to-earnings ratio.**statement](https://dgw.tmarket.io/claims/01a1e751-3025-769e-89ce-f5c5c2bcd583)

[All claims by 瑞銀](https://dgw.tmarket.io/claims?claimant_id=01a1d49e-d995-7396-8810-d1e55c335b54)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b#webpage","@type":"WebPage","description":"statement by 瑞銀, recorded recently — verbatim quote and source citation.","name":"Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A,… — 瑞銀 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Tigermed plans to use about 60% of net cash proceeds for…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715728","text":"泰格醫藥還計劃將約60%的淨現金收益用於海外臨床CRO擴張和併購，20%用於日常運營，剩餘的約20%可能用於分紅或股票回購。","url":"/claims/01a1e751-3083-714b-9c7b-13200f21418b","spokenByCharacter":{"@type":"Person","name":"瑞銀","@id":"/actors/01a1d49e-d995-7396-8810-d1e55c335b54"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
